AbbVie Inc. stock gains as atogepant trial success and HSBC target hike reinforce growth story
Published on 09/10/2026 at 18:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. stock (ISIN US00287Y1091) is trading around USD 251 on the New York Stock Exchange as of September 10, 2026, supported by strong Q2 2026 results and fresh clinical data for its migraine franchise.
Clinical win in menstrual migraine underpins pipeline value
AbbVie announced positive topline results from the Phase 3 LUNA study evaluating atogepant, a calcitonin gene-related peptide receptor antagonist, for the preventive treatment of menstrual migraine in adults, adding another indication to its neurology pipeline as of September 10, 2026, according to GuruFocus.
The same development was highlighted in an FDA events overview, which noted AbbVie shares at USD 251.05, up 0.91%, alongside the atogepant menstrual migraine topline disclosure on September 10, 2026, per MarketBeat.
Q2 2026 earnings show double digit growth
In its most recent reported quarter, AbbVie delivered Q2 2026 revenue of USD 16.99 billion, up 10.2% year over year, while adjusted EPS rose 22.9% to USD 3.65, both above consensus estimates, according to a detailed earnings overview published on September 10, 2026 by BingX.
The same report noted that combined sales of immunology drugs Skyrizi and Rinvoq reached USD 8.03 billion in Q2 2026, representing growth above 24% versus the prior year quarter, partially offsetting a 35.9% year over year decline in Humira revenue, as summarized by BingX.
Management coupled the strong quarter with updated guidance, issuing Q3 2026 adjusted EPS guidance in a range of USD 3.84 to USD 3.88, signaling further earnings growth against the USD 3.65 level just reported for Q2 2026, based on the same BingX overview.
Analysts lift targets as shares trade near recent highs
On the broker side, HSBC reiterated its Buy rating on AbbVie and raised its target price to USD 315 from USD 300 in a biopharma catalyst review dated September 10, 2026, arguing that upcoming pipeline readouts for Skyrizi and Rinvoq could support higher peak sales guidance and lift long term growth expectations, according to Yahoo Finance.
Aggregated analyst data show that AbbVie currently carries a Moderate Buy consensus rating with an average price target of USD 275.95, providing roughly 10% upside from the USD 251 region, based on recent coverage compiled on September 10, 2026 by MarketBeat.
Valuation metrics reflect the strong share performance: AbbVie shares trade around USD 250.91 per share, approximately 13.9% above an estimated intrinsic value of USD 220.20 per share on GF Value, with a trailing price earnings ratio of 70.88 times versus a 5 year median of 50.45 times, as highlighted in the September 10, 2026 analysis from GuruFocus.
Dividend and institutional interest remain supportive
For income oriented investors, AbbVie offers a quarterly dividend of USD 1.73 per share, corresponding to a dividend yield of about 2.8% and a payout ratio near 62%, backed by a three year dividend growth rate of 5.2%, according to the same valuation and income overview from GuruFocus.
Institutional investors continue to accumulate exposure: one recent filing showed Nykredit A/S acquiring 640,558 AbbVie shares during the second quarter of 2026, a position valued at about USD 161.2 million, contributing to total institutional ownership of approximately 70.23% of the company, per an instant alert dated September 10, 2026 from MarketBeat.
Next earnings date and current stock level
The next major checkpoint for AbbVie investors is the Q3 2026 earnings release, which is scheduled for October 23, 2026, according to an earnings calendar update referencing AbbVie dated September 9, 2026 on finanzen.ch.
As of the morning session on September 10, 2026, AbbVie stock opened at USD 251.04 on the New York Stock Exchange, with recent data indicating the shares around USD 251 and modestly higher on the day, while the consensus analyst target of USD 275.95 and HSBC's upgraded USD 315 target frame the current valuation for investors tracking the name.
AbbVie Inc. stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Trading venue: NYSE
- Price (as of September 10, 2026, 09:30): 251.05 USD
- Market capitalization: 444.0 billion USD (as of September 10, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: October 23, 2026
